Connect with us

Technology

Harnessing Generative AI in Healthcare and Improving Cardiometabolic Health with Precision Medicine: Key Opportunities and Insights

Published

on

HOUSTON, Oct. 22, 2024 /CNW/ — In today’s rapidly evolving healthcare landscape, two powerful forces are reshaping how we diagnose, treat, and manage health conditions: Generative artificial intelligence (GenAI) and precision medicine for cardiometabolic health. GenAI promises to revolutionize operational efficiency, financial workflows, and clinical outcomes, while advancements in cardiometabolic treatments pave the way for personalized, patient-centered care. However, these innovations come with challenges, including data privacy concerns and the need for tailored therapeutic options.

Generative AI: Revolutionizing Healthcare Operations

GenAI, powered by advancements like ChatGPT-4, is reshaping healthcare by optimizing workflows, reducing costs, and improving patient care. However, to fully harness its capabilities, healthcare organizations must begin implementing GenAI in foundational areas such as documentation and knowledge management, before scaling across the healthcare value chain. Additionally, organizations need to address cybersecurity concerns, as healthcare faces a growing threat of cyberattacks, with projected costs reaching $90 trillion by 2030.

“Generative AI is transforming healthcare by streamlining/creating workflows, cutting costs, and enhancing patient care. It’s capacity for automation and enhanced decision-making support is critical for healthcare organizations focused on elevating patient outcomes and population health. However, to maximize its benefits, organizations should start with manageable use cases like documentation and knowledge management while also tackling adoption, integration, and cybersecurity challenges. Looking ahead, there are numerous opportunities—from next-generation digital front doors to automated prior authorization processes, and personalized communication, all designed to enhance provider, payer and patient experiences for better health outcomes.”

Nitin Manocha

Growth Expert & Senior Industry Analyst, Frost & Sullivan

Precision Medicine in Cardiometabolic Health

Cardiometabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease, are on the rise globally. Traditional treatment models often lack personalization and fail to address the unique needs of individual patients. Precision health aims to change this by integrating genomics, pharmacogenomics, and omics-based research to develop tailored therapies.

Key Opportunities for Stakeholders in Cardiometabolic Health

Glucagon-Like Peptide-1 (GLP-1)-Based Multi-Agonists: Focus on developing advanced therapies that offer effective weight loss with improved tolerability.Bioinformatics for Data-Driven Research: Harness data analytics to identify novel drug targets.Precision Health Partnerships: Collaborate in high-prevalence regions to enhance diabetes management through tailored interventions.

Embrace the Future of Healthcare Innovation

For a deeper dive into these transformative trends, download our full analysis and join our upcoming webinars, where leading industry experts will discuss the role of GenAI and precision medicine in driving healthcare innovation.

Webinars:

Large Language Models and Generative AI in Healthcare: Exploring Best Practices & Competitive Positioning 

Next-Generation Cardiometabolic Health: Strategic Partnerships for Precision-Driven Innovation 

Stay ahead in the evolving healthcare landscape by registering today.

About Frost & Sullivan:

Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO and the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth initiatives. Frost & Sullivan leverages over 60 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 40 offices on six continents.

To engage with our growth experts for more information, click here

Media Contact: María Briceño
maria.briceno@frost.com

View original content:https://www.prnewswire.com/news-releases/harnessing-generative-ai-in-healthcare-and-improving-cardiometabolic-health-with-precision-medicine-key-opportunities-and-insights-302283257.html

SOURCE Frost & Sullivan

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Ontario Superior Court Awards Over $170 Million in Damages to Mutual Fund Investors in Landmark Class Action Decision

Published

on

By

TORONTO, July 17, 2026 /PRNewswire/ — On July 16, 2026, Justice Markus Koehnen of the Ontario Superior Court of Justice ordered CI Mutual Funds Inc. and AIC Limited to pay Class Members damages and interest in excess of $170 million.

The Market Timing class action, commenced in 2006, alleged that certain mutual fund managers permitted sophisticated offshore hedge fund investors to engage in frequent trading in their funds, that substantially diluted the investment of long-term investors, including retail unitholders, many of whom were retirees.

Rochon Genova has represented the long-term investors since the inception of this case, including before the Supreme Court of Canada, on appeal from an earlier certification motion.  The Supreme Court certified the case in 2013. A subsequent case management order divided the trial into two phases: a trial in respect of liability, and a subsequent trial in respect of damages. The liability trial was held in February, March and June 2022.

On February 13, 2023, Justice Koehnen issued reasons for judgment in respect of the liability trial.  Justice Koehnen found that both CI and AIC breached their duty of care to prevent “market timing” in their funds. The liability decision, indexed as Fischer v. IG Investment, 2023 ONSC 915, is available here.

The damages trial was heard before Justice Koehnen between March 28 and May 16, 2025. Closing submissions were heard on July 30, August 6 and August 7, 2025. In total, Class Counsel spent 41 days in trial on liability (24 days) and damages (17 days). On June 16, 2026, Justice Markus Koehnen of the Superior Court of Justice issued reasons for judgment in respect of the damages trial.

The Court accepted the evidence of the Plaintiffs’ expert, Professor Eric Zitzewitz, and determined that the “Next Day NAV method” of calculating damages was the appropriate methodology to use, as it measures the specific harm that the time zone arbitrage at issue caused, harm referred to as dilution.

Justice Koehnen determined that the “profits method”, the method of calculating damages advocated for by CI’s expert, was not appropriate as it “measures the wrong thing”. The Court determined that on a balance of probabilities, the “prerequisites of using the profits method” had not been met.

Ultimately, with respect to CI, the Court awarded the Plaintiffs $60,480,000 in damages for the harm resulting from CI’s failure to take appropriate steps to prevent market timing by certain Identified Accounts.

The Court also awarded the Plaintiffs damages caused by specific Additional Accounts at CI that were identified by the Plaintiffs’ expert, Professor Zitzewitz, as having engaged in market timing that harmed the unit holders.

With respect to AIC, the Court awarded the Plaintiffs a total of $37,900,659 in damages, which includes damages caused by the Identified Accounts, and Additional Accounts at AIC that were identified by the Plaintiffs’ expert as having engaged in market timing. 

The Court determined the Plaintiffs are also entitled to pre-judgment interest in the amount of 2.8% per annum, to be applied to the damages figures set out above, in addition to costs against both Defendants.

Peter Jervis, a senior partner at Rochon Genova who led the prosecution of this case, stated: “The damages decision sends a clear message that those who fail to safeguard investors from harmful market practices will be held accountable. That this result was achieved after two decades of hard-fought litigation, is a testament to the perseverance of the Representative Plaintiffs and Class Counsel, and to the strength of our judicial system in delivering access to justice in complex cases.”

Joel Rochon, the Managing Partner of Rochon Genova added: “The decision is an important victory not only for the Class Members, but for the integrity of Canadian capital markets. Mutual funds are a cornerstone of the retirement savings of millions of everyday Canadians, and investors are entitled to expect that fund managers will protect them from practices that unfairly dilute the value of their investments.”

The Plaintiffs in this action were represented by Peter Jervis, Joel Rochon, Sarah Fiddes and Jessica Marshall.

For further updates, please visit Rochon Genova’s website here.

View original content:https://www.prnewswire.com/news-releases/ontario-superior-court-awards-over-170-million-in-damages-to-mutual-fund-investors-in-landmark-class-action-decision-302828857.html

SOURCE Rochon Genova

Continue Reading

Technology

Global Commercial Service Robot Shipments Leader KEENON Puts Humanoids to Work at WAIC 2026

Published

on

By

SHANGHAI, July 18, 2026 /PRNewswire/ — At WAIC 2026, KEENON Robotics is bringing humanoid and specialized service robots onto the same stage—not as competing concepts, but as complementary forms of embodied intelligence working across complete commercial service workflows.

According to IDC, KEENON ranked first worldwide in commercial service robot shipments in 2025, while maintaining its leadership in the global delivery robot market. IDC also sees the industry moving toward a more diversified, multi-form future, where different robot types are deployed according to the needs of specific tasks and environments. KEENON first propose such strategy and WAIC showcase brings that trend to life.

At the booth, the newly introduced hotel laundry scenario demonstrates this approach most clearly. Humanoid robots complete operational tasks such as loading and operating washing machines, retrieving clean laundry, and folding garments, while the DINERBOT T9 supports the wider delivery workflow. Together, they show how humanoid and specialized robots can divide responsibilities and collaborate within a real hotel operation.

Beyond the hotel workflow, KEENON applies the same role-based approach to food and retail service. Drawing on years of customer insight from restaurants and stores, XMAN-R1 takes on front-of-house tasks that combine interaction with object handling—from preparing drinks with NOWWA Coffee to responding to customer requests in dessert and retail settings. Rather than presenting isolated demonstrations, these scenarios show how KEENON is extending proven commercial service workflows into new humanoid capabilities, with every task performed autonomously and without teleoperation.

Through its “general-purpose humanoid + specialized service robot” strategy, KEENON is building a practical path for embodied intelligence: humanoids take on flexible operation and interaction tasks, while specialized robots continue to handle high-frequency delivery and cleaning. At WAIC 2026, KEENON is showing not just more robot forms, but a more complete model for commercial deployment.

With more than 100,000 service robots deployed worldwide across over 70 countries and regions, KEENON has been recognized by global renown brands across various sectors and widely deployed at major brands like Burger King, Buffalo Wild Wings, Hilton, BMW, Lego etc. From 10 to 20+ robots operating in single venues like Hotel Around Pyeongchang to a mixed fleet of 8 robots across 6 types at facilities like Shangri-La’s Trader Hotel, making it world-first intelligent hotel with both humanoid and service robot, KEENON delivers proven multi-robot efficiency.

SOURCE KEENON Robotics Co., Ltd.

Continue Reading

Technology

MDT Introduces TMR1370 Ultra-Low-Power Magnetic Switch IC Enabling More Than Two Years of Standby Operation in CGM Devices

Published

on

By

— Next-Generation TMR Magnetic Switch with Ultra-Low 50nA Maximum Supply Current Expands MDT’s Proven CGM Sensor Portfolio

ZHANGJIAGANG, China, July 18, 2026 /PRNewswire/ — MultiDimension Technology Co., Ltd. (MDT), a leading supplier of magnetic sensors and a pioneer in Tunneling Magnetoresistance (TMR) technology, today introduced the TMR1370 ultra-low-power magnetic switch IC, the newest addition to MDT’s magnetic sensing portfolio for continuous glucose monitoring (CGM) devices. Building on the proven TMR1367, TMR1368, and TMR1369 family, the TMR1370 delivers significantly lower power consumption, enhanced voltage compatibility, and a smaller package to enable next-generation CGM systems with ultra-long standby life.

Optimized for battery-powered CGM devices, the TMR1370 features a maximum supply current of only 50nA, with approximately 30nA typical at a 3V supply. When combined with the magnetic wake-up mechanism widely adopted in CGM devices, the TMR1370 enables more than two years of standby operation, helping extend product shelf life while preserving battery capacity for continuous glucose monitoring after activation.

The TMR1370’s exceptional power efficiency is enabled by MDT’s proprietary TMR technology platform, which combines advanced magnetic sensor design, optimized device architecture, and proprietary wafer process technology to achieve high magnetic sensitivity together with ultra-low power consumption. Complementing MDT’s existing X-axis and Z-axis CGM magnetic switch portfolio, the TMR1370 gives system designers greater flexibility to optimize sensor orientation and mechanical layout for a wide variety of CGM architectures while enabling easy migration from previous-generation devices.

Key Features

Enables more than two years of standby operation in battery-powered CGM devices.50nA maximum supply current, approximately 30nA typical at 3V.Wide 1.8V to 4.0V operating-voltage range.Maximum operating point below 40 Gauss for reliable magnetic wake-up detection.X-axis magnetic sensing optimized for compact CGM designs.Miniature DFN5L package (1.6×1.6×0.5mm) for thinner and lighter wearable medical devices.Complements MDT’s proven X-axis and Z-axis CGM magnetic switch portfolio for flexible system design and simplified migration.

Samples of the TMR1370 are available through DigiKey and MDT’s online store at www.tmr-sensors.com. For volume pricing, delivery information, and technical specifications, contact MDT Global Sales at sales@dowayusa.com.

About MDT
MultiDimension Technology was founded in 2010 in Zhangjiagang, Jiangsu Province, China, with branch offices in Shenzhen, Chengdu, and Ningbo in China, Singapore, Tokyo, Japan, and San Jose, Calif., USA. MDT has developed a unique intellectual property portfolio, and its self-owned state-of-the-art TMR manufacturing facilities that can support volume production of high-performance, low-cost TMR magnetic sensors to satisfy the most demanding application needs. Led by its core management team of elite experts and veterans in magnetic sensor technology and engineering services, MDT is committed to creating added value for its customers and ensuring their success. For more information about MDT please visit http://www.multidimensiontech.com.

Media Contacts
MDT sales department, sales@dowayusa.com, sales@dowaytech.com
Tel: +1-650-275-2318 (US), +86-189-3612-1156 (China)

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mdt-introduces-tmr1370-ultra-low-power-magnetic-switch-ic-enabling-more-than-two-years-of-standby-operation-in-cgm-devices-302828591.html

SOURCE MultiDimension Technology Co., Ltd.

Continue Reading

Trending